Image

A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis

Not Recruiting
18 - 100 years of age
Both
Phase N/A

Powered by AI

Overview

This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable Disease-modifying Therapy (DMT) for Relapsing Multiple Sclerosis in Germany. Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to approx. two years of treatment. Additionally, medical history of participants will be collected including disease duration, EDSS, MRI parameters and relapses.

Description

The prerequisite for participation in this observational study is the independent decision of the treating physician and patient to start an approved injectable DMT for RMS as routine medical treatment. This decision must have been made prior to enrollment in this study.

The prospective observational period per patient will be up to approx. two years from the time of consent (2 years +2 months visit window). The observational period will not be dictated by the protocol. The follow-up documentation will take place at a frequency defined as per investigator's discretion. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care, can be performed as telemedicine visits and will take place as per investigator's discretion.

Eligibility

Inclusion Criteria:

  1. Signed informed consent must be obtained prior to participation in the study
  2. Male or female patients aged ≥18 years at enrollment
  3. Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b)
  4. RMS with active disease as defined by Lublin et al. (2014)
  5. Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment
  6. Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive)
  7. Planned initiation or initiation within the past 14 days with an approved injectable DMT for MS as routine medical treatment

Exclusion Criteria:

  1. Patients being treated outside of the approved label
  2. > 5 years since first symptom(s) (leading to MS diagnosis) at enrollment
  3. Previous therapy with any DMT for the treatment of MS prior to enrollment (except within the past 14 days with an approved injectable DMT for MS as routine medical treatment; see Inclusion criteria #7)
  4. Relapse prior to enrollment which has led to a severe deficit relevant to everyday life upon discretion of the investigator after exhaustion of the relapse therapy
  5. Poor recovery from the first two relapses prior to enrollment upon discretion of the investigator
  6. EDSS Functional System Score "Pyramidal Functions" ≥ 2 at enrollment
  7. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab

Study details

Relapsing Multiple Sclerosis

NCT05344469

Novartis Pharmaceuticals

17 January 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.